The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non –Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
Conclusion: Atezolizumab 1,200 mg and pembrolizumab 2 mg/kg every 3 weeks were ordinarily safer than other ICIs. When treating NSCLC, nivolumab had the lowest risk; when treating melanoma, pembrolizumab had the lowest toxicity.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Pneumonia | Skin Cancer | Toxicology | Yervoy